Biotherapeutics, Inc.
Publicly observedBlacksburg, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Blacksburg | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Biotherapeutics, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | DKZNEQL174E3 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant18 Sept 2026Publicly observed
NIH SBIR/STTR award: Immunometabolic Therapeutics for Alzheimer's Disease
USD 500,000.00 · National Institute on Aging · Source: NIH RePORTER (opens in a new tab)
- Grant1 Sept 2026Publicly observed
NIH SBIR/STTR award: Immunometabolic Therapeutics for Multiple Sclerosis
USD 314,363.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant13 Aug 2026Publicly observed
NIH SBIR/STTR award: Novel Immunoregulatory Therapeutics for Bacterial Gastritis
USD 314,363.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant13 Aug 2025Publicly observed
NIH SBIR/STTR award: Next-Gen Oral Therapeutics for Concomitant Clostridioides difficile Infection and IBD
USD 314,363.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant1 Aug 2025Publicly observed
NIH SBIR/STTR award: Novel Therapeutic for SLE
USD 314,363.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant1 Jul 2025Publicly observed
NIH SBIR/STTR award: Next-Gen Oral Therapeutics for Type 2 Diabetes
USD 359,625.00 · National Institute of Diabetes and Digestive and Kidney Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant1 Feb 2025Publicly observed
NIH SBIR/STTR award: The Next Wave of Asthma Therapeutics
USD 347,608.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)
- Grant20 Sept 2023Publicly observed
NIH SBIR/STTR award: A First-in-class Topical Immunoregulatory Therapeutic for Psoriasis
USD 191,331.00 · National Institute of Arthritis and Musculoskeletal and Skin Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant20 Sept 2023Publicly observed
NIH SBIR/STTR award: A First-in-class Topical Immunoregulatory Therapeutic for Psoriasis
USD 1,854,342.00 · National Institute of Arthritis and Musculoskeletal and Skin Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.